{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:14:21Z","timestamp":1789751661615,"version":"4.0.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Backgrounds<\/jats:title><jats:p>The aim of this study was to examine the clinical predictors of Infliximab (IFX) in Crohn\u2019s disease (CD) patients in eastern China and to support further research on the vitamin D remission rate compared to CD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CD who were hospitalized at Xuzhou First People\u2019s Hospital between January 2020 and December 2023 were included in our retrospective analysis. Clinical information was gathered from CD patients at baseline and the endpoint (7th IFX therapy, 38 weeks). To determine the baseline variable [Crohn\u2019s Disease Activity Index (CDAI) &amp;lt; 150] for endpoint clinical remission in patients receiving IFX, and to examine the relationship between blood vitamin D (VIT-D) levels before starting IFX medication and CDAI at Week 38. The potential risk variables were then investigated using univariate, multivariate, and LASSO regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Included were 158 individuals with CD treated with IFX. At baseline, 18.35% of patients had a VIT-D deficit; 64.19% of patients experienced a decrease in VIT-D, and 63.29% of patients achieved clinical remission. The high Vitamin D levels at baseline were independent predictors of clinical remission after IFX therapy, according to univariate, multivariate, and LASSO regression analysis (P &amp;lt; 0.05). Receiver operating characteristic curve analysis revealed that AUC (95%CI) 0.56(0.25-0.95) was the endpoint CDAI (= 150) diagnostic value when the Vit-D level was 19.35 ng\/ml. The corresponding sensitivity and specificity were 75.02% and 79.6%. Endpoint CDAI was independently predicted by male sex, age, BMI, and VIT-D levels &amp;lt;30 ng\/ml (P &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After receiving IFX therapy, CD patients in eastern China with higher VIT-D levels were more likely to achieve clinical remission, particularly those who were male, older, had a higher BMI, and had VIT-D levels below 30 ng\/ml.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1578191","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:58:00Z","timestamp":1749023880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn\u2019s disease patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2016.12.015","article-title":"Vitamin D deficiency and the pathogenesis of Crohn\u2019s disease","volume":"175","author":"White","year":"2018","journal-title":"J Steroid Biochem Mol Bio"},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterolog"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/nu14020269","article-title":"Vitamin D in inflammatory bowel diseases. Mechanisms of action and therapeutic implications","volume":"14","author":"Vernia","year":"2022","journal-title":"Nutrient"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102350","article-title":"Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications","volume":"18","author":"Murdaca","year":"2019","journal-title":"Autoimmun R"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2014.925796","article-title":"The role of vitamin D in gastrointestinal inflammation","volume":"8","author":"Ghaly","year":"2014","journal-title":"Expert Rev gastroenterology hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041083","article-title":"Seven weeks of high-dose vitamin D treatment reduces the need for infliximab dose-escalation and decreases inflammatory markers in crohn\u2019s disease during one-year follow-up","volume":"13","author":"Bendix","year":"2021","journal-title":"Nutrients"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040709","article-title":"Vitamin D and autoimmune rheumatic diseases","volume":"15","author":"Athanassiou","year":"2023","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063154","article-title":"Autoimmune thyroiditis and vitamin D","volume":"25","author":"Dur\u00e1-Trav\u00e9","year":"2024","journal-title":"Int J Mol Sc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh7954","article-title":"Vitamin D regulates microbiome-dependent cancer immunity","volume":"384","author":"Giampazolias","year":"2024","journal-title":"Sci (New York NY)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/0148607113506013","article-title":"and Crohn\u2019s disease in the adult patient: a review","volume":"38","author":"Basson A. Vitamin","year":"2014","journal-title":"JPEN J parenteral enteral nutrition"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041378","article-title":"Sarcopenia and vitamin D deficiency in patients with crohn\u2019s disease: pathological conditions that should be linked together","volume":"13","author":"Palmese","year":"2021","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2023.02.004","article-title":"Vitamin D and microbiome: molecular interaction in inflammatory bowel disease pathogenesis","volume":"193","author":"Aggeletopoulou","year":"2023","journal-title":"Am J pathology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02144","article-title":"Links between inflammatory bowel disease and chronic obstructive pulmonary disease","volume":"11","author":"Raftery","year":"2020","journal-title":"Front Immuno"},{"key":"B15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10238-024-01483-0","article-title":"Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn\u2019s disease patients in western China","volume":"24","author":"Song","year":"2024","journal-title":"Clin Exp medicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1751-2980.12994","article-title":"Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)","volume":"22","year":"2021","journal-title":"J digestive Di"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Meta"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1556\/oh.2013.29750","article-title":"Vitamin D level in Hungarian patients with inflammatory bowel diseases","volume":"154","author":"L\u0151rinczy","year":"2013","journal-title":"Orvosi hetilap"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohn\u2019s colitis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13807","article-title":"The gut microbiota metabolite capsiate regulate SLC2A1 expression by targeting HIF-1\u03b1 to inhibit knee osteoarthritis-induced ferroptosis","volume":"22","author":"Guan","year":"2023","journal-title":"Aging Cel"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet (London England)"},{"key":"B23","article-title":"Crohn\u2019s disease: diagnosis and management","volume":"98","author":"Veauthier","year":"2018","journal-title":"Am Family physician"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.medcli.2017.10.036","article-title":"Crohn\u2019s disease","volume":"151","author":"Ballester Ferr\u00e9","year":"2018","journal-title":"Medicina clinica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet (London England)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Sci (New York NY)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.01.006","article-title":"Therapeutic implications of the TLR and VDR partnership","volume":"13","author":"Liu","year":"2007","journal-title":"Trends Mol medicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/1751-2980.12565","article-title":"Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis","volume":"19","author":"Sch\u00e4ffler","year":"2018","journal-title":"J digestive diseases"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.11.040","article-title":"Higher predicted vitamin D status is associated with reduced risk of Crohn\u2019s disease","volume":"142","author":"Ananthakrishnan","year":"2012","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0148607110381267","article-title":"Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life","volume":"35","author":"Ananthakrishnan","year":"2011","journal-title":"JPEN J parenteral enteral nutrition"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000001443","article-title":"Vitamin D in children with inflammatory bowel disease: A randomized controlled clinical trial","volume":"55","author":"El Amrousy","year":"2021","journal-title":"J Clin gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5409\/wjcp.v8.i1.1","article-title":"Vitamin D therapy in children with inflammatory bowel disease: A systematic review","volume":"8","author":"Rigterink","year":"2019","journal-title":"World J Clin pediatrics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.10.011","article-title":"Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases","volume":"12","author":"Ananthakrishnan","year":"2014","journal-title":"Clin gastroenterology hepatology: Off Clin Pract J Am Gastroenterological Association"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000502515","article-title":"Distinct association of serum vitamin D concentration with disease activity and trough levels of infliximab and adalimumab during inflammatory bowel disease treatment","volume":"101","author":"Mechie","year":"2020","journal-title":"Digestion"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.739285","article-title":"Influence of vitamin D3 supplementation on infliximab effectiveness in chinese patients with crohn\u2019s disease: A retrospective cohort study","volume":"8","author":"Mechie","year":"2021","journal-title":"Front nutrition"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6675401","article-title":"Correlation between treatment outcomes and serum vitamin D levels as well as infliximab trough concentration among chinese patients with crohn\u2019s disease","volume":"2023","author":"Song","year":"2023","journal-title":"Gastroenterology Res practice"},{"key":"B37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2050640615572176","article-title":"Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn\u2019s disease: Results from a randomised double-blind placebo-controlled study","volume":"3","author":"Song","year":"2015","journal-title":"United Eur gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195715","article-title":"Pleiotropic effects of vitamin D in patients with inflammatory bowel diseases","volume":"3","author":"Raftery","year":"2022","journal-title":"J Clin medicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00105.2015","article-title":"Vitamin D receptor pathway is required for probiotic protection in colitis","volume":"309","author":"Wu","year":"2015","journal-title":"Am J Physiol Gastrointestinal liver Physio"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307436","article-title":"Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis","volume":"64","author":"Wu","year":"2015","journal-title":"Gut"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666161026124951","article-title":"Interplay of immunity and vitamin D: interactions and implications with current IBD therapy","volume":"24","author":"Abdo","year":"2017","journal-title":"Curr medicinal Che"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.53","article-title":"Association of vitamin D level with clinical status in inflammatory bowel disease: A 5-year longitudinal study","volume":"111","author":"Kabbani","year":"2016","journal-title":"Am J gastroenterology"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1651209","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1578191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:08:22Z","timestamp":1752577702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1578191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1578191"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1578191","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1651209","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1578191"}}